May, 2005

U.S.A.
News / Therapeutic Area News
Data from Tarceva-TM- Clinical Trial Program Presented at American Society of Clinical Oncology Annual Meeting; EGFR Amplification / Mutation Analysis from the Registration BR.21 Trial Presented
ORLANDO, Fla., May 16, 2005 -- OSI Pharmaceuticals (Nasdaq:OSIP) provided an informational update summarizing highlights from presentations on the analysis of EGFR mutation and gene amplification...
Read More
U.S.A.
News / Therapeutic Area News
Phase III Study of Tarceva in Combination With Chemotherapy Improves Survival in Pancreatic Cancer Patients
ORLANDO, Fla., May 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today presented additional data from a randomized Phase III...
Read More
U.S.A.
News / Therapeutic Area News
Anti-Fungal Agent MYCAMINE™ Available to Physicians
Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent MYCAMINE™ (micafungin sodium) for Injection to hospitals nationwide. The U.S. Food...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals and Genentech Announce Filing of a Supplemental New Drug Application to the FDA for Tarceva -TM- in Pancreatic Cancer
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 2, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that OSI submitted a...
Read More

Mar, 2005

U.S.A.
News / Therapeutic Area News
Fujisawa Healthcare, Inc. and Roche Announce Co-promotion of MYCAMINE™
Fujisawa Healthcare, Inc. and Roche Pharmaceuticals today announced a partnership for the U.S. co-promotion of MYCAMINE™ (micafungin sodium) injection, Fujisawa's newly approved product for the...
Read More